Weekly roundup: A successful fundraising for One Biosciences, the Novo Nordisk Foundation’s acquisition of the world’s most powerful quantum computer, Xeltis’ positive data for Xabg, and Optimum TV’s launch of its ‘Thought Leaders’ series

/in

One Biosciences announces €15 Million Series A financing to advance clinical single cell profiling One Biosciences, a precision oncology techbio company pioneering clinical grade single-cell tumour transcriptomic profiling, announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. […]

Read more

Hot topic: A patently obvious opportunity?

/in

The patent cliff is looming and Big Pharma firms are concerned. Hungry to fill revenues holes which will soon start to open up, they are on the lookout for tasty biotechs with oven-ready assets. Last week, Merck & Co pounced – with the purchase of our client London-based Verona Pharma for a cool $10 billion. […]

Read more

Weekly roundup: A week of wins – Big deals, big awards, big news!

/in ,

Firstly, congratulations to the team at Verona Pharma on their incredible $10bn dollar deal with Merck! And to Actithera on their oversubscribed $75.5M Series A – a great achievement in the current market. Huge congratulations also go to the incomparable Clive Cookson on receiving the Lifetime Achievement Award at the Association of British Science Writers […]

Read more

Have we reached “peak drugs pricing”?

/in

Challenges to pharma charging premium prices for branded drugs are not new.  Think of President Biden’s attempts to drive down prices with the Inflation Reduction Act. Or the UK’s strategy of capping the price the NHS pays for branded medicines with its VPAG rebate scheme.  But President Trump’s “most favoured nation” policy – which attempts […]

Read more

Weekly roundup: Dealmaker’s insights, a new CEO, plus… the UK Government’s got a plan!

/in

Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio Vesper Bio a clinical stage biotech developing an oral therapy for frontotemporal dementia, announces the appointment of Jacob Falck Hansen as Chief Executive Officer. Jacob brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He is a Partner at […]

Read more
© Optimum Strategic Communications.